Literature DB >> 7697798

Inhibitory effects of sulfation inhibitors on initiation of pancreatic ductal carcinogenesis by N-nitrosobis(2-oxopropyl)amine in hamsters.

M Tsutsumi1, O Noguchi, S Okita, K Horiguchi, E Kobayashi, K Tamura, T Tsujiuchi, A Denda, Y Konishi, K Iimura.   

Abstract

The effects of dehydroepiandrosterone sulfate (DHAS), a typical hydroxysteroid sulfotransferase (HSTase) inhibitor, and of 3'-phosphoadenosine 5'-phosphate (PAP), a nonspecific sulfation inhibitor on N-nitrosobis(2-oxopropyl)-amine (BOP)-induced initiation were examined in a rapid production model for pancreatic carcinomas in hamsters in order to elucidate the involvement of sulfotransferase in the metabolic activation of beta-oxypropylnitrosamines. While neither low nor high doses of DHAS and PAP exerted any significant influence on the incidence of ductal lesions including carcinomas, the high dose of DHAS (350 mg/kg body wt) and a both low (90 mg/kg) and high (180 mg/kg) doses of PAP reduced the mean numbers of pancreatic ductal adenocarcinomas. The high dose of PAP also reduced the number of all ductal lesions combined. The results thus suggest that metabolic activation with STase is involved in BOP-induced pancreatic ductal carcinogenesis in hamsters, and support the hypothesis that BOP is metabolized to beta-hydroxyalkylnitrosamines followed by activation to proximate sulfuric acid esters by HSTase.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7697798     DOI: 10.1093/carcin/16.3.457

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  2 in total

1.  Inhibition of phenolsulphotransferase by salicylic acid: a possible mechanism by which aspirin may reduce carcinogenesis.

Authors:  R M Harris; R J Hawker; M J Langman; S Singh; R H Waring
Journal:  Gut       Date:  1998-02       Impact factor: 23.059

2.  The role of aspirin in carcinogenesis.

Authors:  G J Caine; S T Kehoe; G Y H Lip
Journal:  Br J Cancer       Date:  2002-11-18       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.